Evidence map›Paper›PMID 40126733›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Hematological toxicity of [

Meryl Maria Vilangattil, Abir Swaidan, Jonathan Godinez, Marco F Taddio, Johannes Czernin, Christine E Mona, Giuseppe Carlucci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meryl Maria VilangattilAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 650 Charles E Young Dr S, Los Angeles, Los Angeles, California, California, 90095, USA. merylmaria7@gmail.com.ORCID http://orcid.org/0009-0000-8083-8097
Abir SwaidanAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 650 Charles E Young Dr S, Los Angeles, Los Angeles, California, California, 90095, USA.
Jonathan GodinezAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 650 Charles E Young Dr S, Los Angeles, Los Angeles, California, California, 90095, USA.
Marco F TaddioAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 650 Charles E Young Dr S, Los Angeles, Los Angeles, California, California, 90095, USA.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 650 Charles E Young Dr S, Los Angeles, Los Angeles, California, California, 90095, USA.
Christine E MonaAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 650 Charles E Young Dr S, Los Angeles, Los Angeles, California, California, 90095, USA.
Giuseppe CarlucciAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 650 Charles E Young Dr S, Los Angeles, Los Angeles, California, California, 90095, USA. GCarlucci@mednet.ucla.edu.ORCID http://orcid.org/0000-0001-7494-335X

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

backgroundProstate cancer (PC) has a 34% 5-year survival rate after progressing to metastatic castration-resistant prostate cancer (mCRPC), which occurs in 20-30% of cases. Treatments like chemotherapy, immunotherapy, and PSMA-targeted radioligand therapy (RLT) show promise, but challenges remain with tumor resistance, side effects, and dose-limiting toxicity in kidneys and bone marrow. This study investigated the hematotoxicity, treatment efficacy, and recovery after [

methodTwenty-five male C57BL/6 mice were inoculated with RM1-PGLS cells and monitored using [

resultsBoth treatments significantly slowed tumor progression and extended survival. [

conclusionBoth [

Indexed as

Actinium-225HematotoxicityLuetitium-177PCPSMA-617RLT

Identifiers

PMID40126733
PMCPMC11933494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.